AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
Executive Summary
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting
You may also be interested in...
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.
Genentech Bid To Gain Full Approval For Avastin On Amassed PFS Data Gets July ODAC Hearing
Roche division also seeks approval for bevacizumab in new combinations based on AVADO and RIBBON-1 trial results, but the question remains whether the progression-free survival endpoint used in all the trials is sufficient for full approval.